--- title: "ADC Therapeutics SA (ADCT) news: offering" url: "https://aibio.space/companies/adc-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ADCT offering news: ADC Therapeutics agrees to $86.6 million PIPE and plans loan cut to $50.0 million. ADC Therapeutics SA (NYSE: ADCT), Switzerland." --- ADCT ADC Therapeutics SA NYSE · Switzerland # ADC Therapeutics SA (ADCT) news ADCT offering news Debt Financing · 2026-10-13 ## [ADC Therapeutics agrees to $86.6 million PIPE and plans loan cut to $50.0 million](https://aibio.space/news/adc-therapeutics-agrees-86-6-million-pipe-plans-loan-cut-50-0-million/) ADC Therapeutics agreed to an $86.6 million private placement and to cut its senior loan to $50.0 million, and its royalty holder gave up a $150 million change-of-control payment. The changes depend on the placement closing, and expected cash at September 30, 2026 was $189.2 million, against $219.1 million at June 30. ## Latest ADC Therapeutics SA news 1. 2026-02-23 Financings [ADC Therapeutics amends HCR royalty deal, issues warrants for 9,834,776 shares](https://aibio.space/news/adc-therapeutics-amends-hcr-royalty-deal-issues-warrants-9-834-776/) The February 18, 2026 amendment sets the change-of-control payment to HCR at $150 million or $200 million and revises a buyout option. HCR received warrants at $3.8130 per share. 2. 2025-06-12 Distress [ADC Therapeutics plans about 30% workforce cut, U.K. closure, $100 million private placement](https://aibio.space/news/adc-therapeutics-plans-about-30-percent-workforce-cut-u-k-closure-100/) ADC Therapeutics approved a restructuring on June 11, 2025 that closes its U.K. research facility and cuts about 30% of its global workforce. The same day it agreed to a $100 million private placement priced at $3.53 per share. ## ADC Therapeutics SA at a glance - **Ticker**: ADCT - **Listing**: NYSE - **Country**: Switzerland - **Cash, Jun 30, 2026**: $219.1 million ### Related companies - [Santhera Pharmaceuticals Holding](https://aibio.space/companies/santhera-pharmaceuticals/) SIX: SANN - [Addex Therapeutics](https://aibio.space/companies/addex-therapeutics/) SIX: ADXN - [Novartis](https://aibio.space/companies/novartis/) SIX: NOVN - [Galderma Group](https://aibio.space/companies/galderma/) SIX: GALD - [Curatis Holding](https://aibio.space/companies/curatis/) SIX: CURN - [BeOne Medicines](https://aibio.space/companies/beone-medicines/) SSE: 688235 - [Sandoz Group](https://aibio.space/companies/sandoz/) SIX: SDZ - [Basilea Pharmaceutica](https://aibio.space/companies/basilea-pharmaceutica/) SIX: BSLN ### Also on NYSE - [Bausch & Lomb](https://aibio.space/companies/bausch-lomb/) BLCO - [STERIS](https://aibio.space/companies/steris/) STE - [Baxter International](https://aibio.space/companies/baxter-international/) BAX - [3M CO](https://aibio.space/companies/3m/) MMM - [Goldman Sachs Group](https://aibio.space/companies/goldman-sachs/) GS - [Biohaven](https://aibio.space/companies/biohaven/) BHVN ## What ADC Therapeutics SA does ADC Therapeutics is a commercial-stage antibody drug conjugate company headquartered in Lausanne, Switzerland, with operations in New Jersey. Its focus is ZYNLONTA, loncastuximab tesirine-lpyl, a CD19-directed antibody drug conjugate that received accelerated approval from the FDA and conditional approvals from the European Commission, the China National Medical Products Administration and Health Canada for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The company is working to move ZYNLONTA into earlier lines of DLBCL through the confirmatory Phase 3 LOTIS-5 trial with rituximab and the Phase 1b LOTIS-7 trial with a bispecific combination, and into indolent lymphomas through investigator-initiated trials. Partnerships extend ZYNLONTA outside the United States. Tanabe Pharma holds a license in Japan, a joint venture with Overland Pharmaceuticals covers China, Singapore and Taiwan, and Swedish Orphan Biovitrum AB holds rights in the other regions excluding the US. Its pipeline includes ADCT-241, an exatecan-based PSMA-targeting antibody drug conjugate for which IND-enabling activities were completed at the end of 2025. | Product or program | What it is | Stage | |---|---|---| | ZYNLONTA (loncastuximab tesirine-lpyl) | CD19-directed antibody drug conjugate for relapsed or refractory DLBCL | accelerated approval (FDA); conditional approvals (EC, NMPA, Health Canada) | | ADCT-241 | Exatecan-based PSMA-targeting antibody drug conjugate | IND-enabling activities completed | Summarised from the company's [10-K filed Mar 10, 2026](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/adc-20251231.htm). ## ADC Therapeutics SA annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$81.4 million](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/) | [$70.8 million](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/) | | Research and development | [$104.0 million](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/) | [$109.6 million](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/) | | Net income (loss) | [-$142.6 million](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/) | [-$157.8 million](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/) | | Cash from operations | [-$141.2 million](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/) | [-$123.8 million](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/) | | Cash and equivalents | [$261.3 million](https://www.sec.gov/Archives/edgar/data/1771910/000162828026056711/) | [$250.9 million](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $219.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ADC Therapeutics SA Has ADC Therapeutics SA raised money recently? Our latest story on this, dated Oct 13, 2026: "ADC Therapeutics agrees to $86.6 million PIPE and plans loan cut to $50.0 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/adc-therapeutics-agrees-86-6-million-pipe-plans-loan-cut-50-0-million/). What is the ticker symbol of ADC Therapeutics SA? ADC Therapeutics SA trades under the ticker ADCT on NYSE. Where is ADC Therapeutics SA listed? ADC Therapeutics SA is listed on NYSE. What is the SEC CIK of ADC Therapeutics SA? The SEC Central Index Key (CIK) for ADC Therapeutics SA is 1771910. Its filings are on SEC EDGAR. How many shares does ADC Therapeutics SA have outstanding? 127,667,695 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is ADC Therapeutics SA listed under? Our directory records ADC Therapeutics SA under Switzerland. What does ADC Therapeutics SA do? Our directory classifies ADC Therapeutics SA as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of ADC Therapeutics SA? The ISIN recorded for ADC Therapeutics SA is CH0499880968. Does aibio.space cover ADC Therapeutics SA? aibio.space lists ADC Therapeutics SA among 2,820 public biotech companies and publishes its news here as stories appear. Where is ADC Therapeutics SA incorporated? SEC records list its state or country of incorporation as V8. What does ADC Therapeutics SA develop? ADC Therapeutics is a commercial-stage antibody drug conjugate company headquartered in Lausanne, Switzerland, with operations in New Jersey. Its focus is ZYNLONTA, loncastuximab tesirine-lpyl, a CD19-directed antibody drug conjugate that received accelerated approval from the FDA and conditional approvals from the European Commission, the China National Medical Products Administration and Health Canada for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. What is ZYNLONTA (loncastuximab tesirine-lpyl) from ADC Therapeutics SA? ZYNLONTA (loncastuximab tesirine-lpyl): CD19-directed antibody drug conjugate for relapsed or refractory DLBCL Stage: accelerated approval (FDA); conditional approvals (EC, NMPA, Health Canada). What is ADCT-241 from ADC Therapeutics SA? ADCT-241: Exatecan-based PSMA-targeting antibody drug conjugate Stage: IND-enabling activities completed. What was ADC Therapeutics SA's revenue last year? $81.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is ADC Therapeutics SA profitable? ADC Therapeutics SA reported a net loss of $142.6 million for the fiscal year ended Dec 31, 2025, and used $141.2 million of cash in operations, per its annual report to the SEC. ## Investor discussion: ADC Therapeutics SA Members talk about ADC Therapeutics SA (ADCT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ADC Therapeutics SA, newest first. Each line links the filing it comes from. 1. 2026-10-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771910/000095010326015465/dp254756_ex9901.htm) 2. 2026-06-24 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/dp248849_ex9901.htm) 3. 2026-02-23 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771910/000095010326002466/dp241844_8k.htm) 4. 2025-10-14 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771910/000095010325013103/dp235779_ex9901.htm) 5. 2025-09-30 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771910/000095010325012514/dp235214_ex9901.htm) 6. 2025-06-12 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.05,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1771910/000095010325007282/dp230070_8k.htm) ## Press releases Headlines of ADC Therapeutics SA's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-29 PR Newswire [ADC Therapeutics Announces ZYNLONTA® Updates in Japan](https://www.prnewswire.com/news-releases/adc-therapeutics-announces-zynlonta-updates-in-japan-302922936.html) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:ADCT on TradingView](https://www.tradingview.com/symbols/NYSE-ADCT/). ## SEC filings and registration - **SEC name**: ADC Therapeutics SA - **CIK**: 1771910 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ADCT (NYSE) - **State or country of incorporation**: V8 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: BIOPOLE, EPALINGES, Switzerland, 1066 - **Phone**: 41 21 653 02 00 - **Shares outstanding**: 127,667,695 as of 2026-08-03 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1771910/000095010326015465/dp254756_8k.htm) filed 2026-10-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1771910/000162828026056711/adc-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1771910/000095010326012287/dp251718_8k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1771910/000095010326010195/dp249055_8k.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/dp248849_8k.htm) filed 2026-06-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/dp247928_8k.htm) filed 2026-06-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/dp247757_8k.htm) filed 2026-06-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1771910/000162828026029819/adc-20260331.htm) filed 2026-05-04 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001771910), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ADC Therapeutics SA is a public biotech or pharmaceutical company listed on NYSE under the ticker ADCT, recorded under Switzerland. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ADC Therapeutics SA - **Ticker**: ADCT - **Listing**: NYSE - **Country or territory**: Switzerland - **Business scope**: Pharmaceuticals: Major - **ISIN**: CH0499880968 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NYSE-ADCT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/adc-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ADC Therapeutics SA (ADCT) news: offering", 2026-10-31, https://aibio.space/companies/adc-therapeutics/